Mandate

Vinge advises Orkla in connection with the acquisition of Zeelandia AB

Vinge has advised Orkla in connection with Orkla Food Ingredients AS’s acquisition of Zeelandia AB from Koninklijke Zeelandiaa Groep B.V.

Orkla is a leading actor of trademark and concept solutions for trading in convenience goods and large-scale catering institutions within the Nordic Region, Baltic Region, Central Europe and India. In 2018, the group’s turnover was NOK 41 billion and had approximately 18 500 employees. Orkla Food Ingredients is the largest actor within the bakery ingredients industry in the Nordic Region, and distributes products to 21 countries in total. The primary product categories are yeast, butter, plant‑based products, marzipan and margarine. Zeelandia AB’s product portfolio includes ingredients for all types of bread, buns, cakes and pastries as well as separating agents, balancing oils and food fillers, and is a strategic acquisition in order to strengthen Orkla’s position on the Nordic market. Following the acquisition, Zeelandia AB will change its name to Credin Sverige AB.

The acquisition is conditional upon the consent of the relevant competition authorities and other customary closing conditions.

Vinge’s team consisted of partners Peter Sundgren and Johan Karlsson together with, among others, associates Filip Öhrner, Christina Odengran, Isabelle Jengsell, Christoffer Nordin, Karin Virding, Lisa Ullman and project assistant Viktoria Owetz. Trine Osen Bergquist and Sebastian Örndahl provided competition law advice.

Related

Vinge has advised Egetis Therapeutics in connection with a directed share issue

Vinge has advised Egetis Therapeutics AB (publ) (“Egetis Therapeutics”), listed on Nasdaq Stockholm, in connection with a directed share issue whereby Egetis Therapeutics raised proceeds of approximately SEK 183 million before transaction costs.
October 06, 2025

Vinge worked with funds advised by Agilitas on the buy-out of Vivicta (previously Tietoevry Tech Services), including on the issuance of senior secured bonds and on entering into a super senior RCF

Vinge, together with O’Melveny as lead counsel and Avance, worked with funds advised by Agilitas Private Equity LLP (“Agilitas”), the pan-European mid-market private equity firm, in their backing of Vivicta. The buy-out was previously announced on 24 March 2025 and closed on 2 September 2025.
October 03, 2025

Vinge has advised Hansa Biopharma in connection with a directed share issue of approx. SEK 671.5 million

Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue through which the company raises proceeds of approx. SEK 671.5 million before transaction costs.
October 03, 2025